Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zenocutuzumab in NRG1 fusion-positive solid tumors (eNRGy)
2024-512358-78-00Phase 2Authorised
- Sponsor
- Partner Therapeutics
- Start
- Apr 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 2, open-label trial of zenocutuzumab in Non-hematologic malignancy, non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Partner Therapeutics. Primary endpoints: Adverse events and dose-limiting toxicities, Safety and antitumor activity and 1 more. Planned start Apr 2024; status: authorised.
02
Drugs
zenocutuzumab
03
Conditions
Non-hematologic malignancynon-small cell lung cancer (NSCLC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-512358-78-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512358-78-00.